

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) An agent for preventing and/or treating hematologic malignancies, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 in the sequence listing.

2. (Currently amended) ~~An~~ The agent for preventing and/or treating hematologic malignancies of claim 1, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 8 and 10 in the sequence listing.

3. (Original) The agent for preventing and/or treating hematologic malignancies according to Claim 2, further comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 6, 7 and 9 in the sequence listing.

4. (Currently amended) ~~An~~ The agent for preventing and/or treating hematologic malignancies of claim 1, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2 and 4 in the sequence listing.

5. (Currently amended) ~~An~~ The agent for preventing and/or treating hematologic malignancies of claim 1, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 10 in the sequence listing.

6. (Currently amended) ~~An~~ The agent for preventing and/or treating hematologic malignancies of claim 1, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 8 in the sequence listing.

7. (Currently amended) The agent for preventing and/or treating hematologic malignancies according to ~~any one of Claims 1 to 6~~ claim 1, further comprising an adjuvant.

8. (Currently amended) The ~~preventing and/or treating~~ agent according to ~~any one of Claims 1 to 7~~ claim 1, wherein the hematologic malignancies are hematologic malignancies having HLA-A24 molecules on their cell surface.

9. (Currently amended) The ~~preventing and/or treating~~ agent according to ~~any one of Claims 1 to 7~~ claim 1, wherein the hematologic malignancies are hematologic malignancies which have HLA-A24 molecules on their cell surface and express a protein containing the peptide that is an active ingredient for the preventing and/or treating agent.

10. (Currently amended) The agent for preventing and/or treating hematologic malignancies according to ~~any one of Claims 1 to 9~~ claim 1, wherein the agent is used as a cancer vaccine for the hematologic malignancies.

11. (Currently amended) A medicament for preventing and/or treating hematologic malignancies having HLA-A24 molecules on their cell surface, comprising the agent of claim 1 comprising at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 8 and 10 in the sequence listing and an adjuvant.

12. (Currently amended) A method for preventing and/or treating hematologic malignancies that have HLA-A24 molecules on their cell surface, comprising administering a therapeutically effective amount of the agent of claim 1 comprising at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 8 and 10 in

the sequence listing together with an adjuvant.

13. (New) The agent for preventing and/or treating hematologic malignancies according to claim 2, further comprising an adjuvant.

14. (New) The agent for preventing and/or treating hematologic malignancies according to claim 3, further comprising an adjuvant.

15. (New) The agent for preventing and/or treating hematologic malignancies according to claim 4, further comprising an adjuvant.

16. (New) The agent for preventing and/or treating hematologic malignancies according to claim 5, further comprising an adjuvant.

17. (New) The agent for preventing and/or treating hematologic malignancies according to claim 6, further comprising an adjuvant.

18. (New) The agent according to claim 2, wherein the hematologic malignancies are hematologic malignancies having HLA-A24 molecules on their cell surface.

19. (New) The agent according to claim 3, wherein the hematologic malignancies are hematologic malignancies having HLA-A24 molecules on their cell surface.